Clinical Trial Update: A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc) [Phase 2]

View source ↗

Summary

A Phase 2 double-blind trial evaluating BMS-986020 versus placebo in diffuse cutaneous systemic sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Systemic Sclerosis

Drugs mentioned

• BMS-986020

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Scleroderma | Phase 2 | Status: WITHDRAWN